Science Explorer Back to mapMap
Discussion
Institution · Veracity Clinical Research

Most cited papers from Veracity Clinical Research

Veracity Clinical Research

What are the most cited papers from Veracity Clinical Research?

The most cited paper from Veracity Clinical Research is "Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials" (Richard G B Langley, Boni Elizabeth Elewski, Mark Lebwohl et al., 2014), with 2,004 citations. Next come "Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis" (826) and "Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*" (627).

Showing 50 of 79 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials Richard G B Langley, Boni Elizabeth Elewski, Mark Lebwohl et al. · New England Journal of Medicine Open access 9 Jul 2014 2,004
2 Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis Mark Lebwohl et al. · New England Journal of Medicine Open access 30 Sep 2015 826
3 Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)* Andreas Wollenberg et al. · British Journal of Dermatology Open access Oct 2020 627
4 Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials Eric Lawrence Simpson et al. · British Journal of Dermatology 30 Jan 2020 391
5 Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study Kim Alexander Papp, Hervé Bachelez, Antonio Costanzo et al. · Journal of the American Academy of Dermatology Open access 10 Mar 2017 140
6 Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study Miriam Calao, Jodie L. Wilson, Lynda J. Spelman et al. · PLoS ONE Open access 24 Jul 2018 106
7 Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis Kim Alexander Papp, Hervé Bachelez, Antonio Costanzo et al. · British Journal of Dermatology Open access 29 Jul 2017 82
8 Crisaborole and its Potential Role in Treating Atopic Dermatitis: Overview of Early Clinical Studies LT Zane, Sanjay Chanda, Kurt Jarnagin et al. · Immunotherapy Open access 10 Jun 2016 73
9 Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials Mark Lebwohl, Richard Bruce Warren, Howard L. Sofen et al. · British Journal of Dermatology Open access 12 Jan 2024 68
10 Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in A ustralia Jo‐Ann See, Stephen P. Shumack, Dedee Frances Murrell et al. · Australasian Journal of Dermatology Open access 31 May 2015 65
11 Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years April Wang Armstrong, Mark Lebwohl, Richard Bruce Warren et al. · JAMA Dermatology Open access 27 Nov 2024 52
12 A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients Miko Yamada, Dennis Michael Miller, Melinda Lowe et al. · Contemporary Clinical Trials Communications Open access 4 Aug 2021 40
13 Atopic Dermatitis Treated Safely with Dupilumab during Pregnancy: A Case Report and Review of the Literature Yolanka Lobo, Ruby Chia‐Lin Lee, Lynda J. Spelman · Case Reports in Dermatology Open access 4 May 2021 40
14 Rademikibart ( CBP ‐201), a next‐generation monoclonal antibody targeting human IL‐4Rα : Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis Junying Wang, Jeffery White, Kenneth J. Sansone et al. · Clinical and Translational Science Open access 17 Oct 2023 23
15 Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study Kurt Gebauer, Lynda J. Spelman, Paul Steven Yamauchi et al. · Journal of the American Academy of Dermatology Open access 28 Mar 2024 21
16 Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials Kenneth B. Gordon, Kristian Reich, Jeffrey Crowley et al. · Journal of Dermatological Treatment Open access 30 Apr 2020 21
17 Debunking the Myth of Wool Allergy: Reviewing the Evidence for Immune and Non-immune Cutaneous Reactions Michaela Zallmann, Peter Kenneth Smith, Mimi L.K. Tang et al. · Acta Dermato Venereologica Open access 2017 21
18 Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23 Katherine Darch, Teagan Holland, Lynda J. Spelman · Case Reports in Medicine Open access 24 Jul 2020 18
19 ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis Emma Guttman‐Yassky, Eric Lawrence Simpson, Robert Bissonnette et al. · Immunotherapy Open access 22 Jan 2025 17
20 1061 The safety of topical cannabidiol (CBD) for the treatment of acne L. Spleman, Rodney Daniel Sinclair, Martha M. Freeman et al. · Journal of Investigative Dermatology Open access 19 Apr 2018 16
21 Squamous cell carcinoma and keratoacanthomas are biologically distinct and can be diagnosed by light microscopy: a review Johan Selmer, Torsten Skov, Lynda J. Spelman et al. · Histopathology 20 Jun 2016 13
22 Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin) Emma Guttman‐Yassky, Stephan Weidinger, Eric Lawrence Simpson et al. · Dermatology and Therapy Open access 23 Jun 2025 12
23 Efficacy and safety of ingenol mebutate gel in field treatment of actinic keratosis on full face, balding scalp, or approximately 250 cm2 on the chest: A phase 3 randomized controlled trial C. William Hanke, Lorne E. Albrecht, Torsten Skov et al. · Journal of the American Academy of Dermatology 30 Jul 2019 11
24 AB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials Richard Bruce Warren, A. Armstrong, M. Gooderham et al. · Annals of the Rheumatic Diseases Open access Jun 2022 10
25 Biosimilars: what the dermatologist should know Paul Steven Yamauchi, J. Crowley, Primal P Kaur et al. · Journal of the European Academy of Dermatology and Venereology 23 Jan 2018 10
26 Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial Howard L. Sofen, Kurt Gebauer, Lynda J. Spelman et al. · Journal of the American Academy of Dermatology Open access 23 Dec 2024 9
27 Randomized, Placebo-Controlled Phase 1/2 Study to Determine the Appropriate ATX-101 Concentration for Reduction of Submental Fat Greg Julian Goodman, Lynda J. Spelman, Nicholas J. Lowe et al. · Dermatologic Surgery 3 Jun 2021 9
28 Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial Jashin J. Wu, Lynda J. Spelman, Jerry L. Tan et al. · Dermatology and Therapy Open access 28 Jan 2021 9
29 Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program Richard Bruce Warren, Howard L. Sofen, Shinichi Imafuku et al. · SKIN The Journal of Cutaneous Medicine Open access 16 Nov 2022 8
30 Toxoplasmosis in a patient receiving ixekizumab for psoriasis Yolanka Lobo, Teagan Holland, Lynda J. Spelman · JAAD Case Reports Open access 18 Feb 2020 8
31 Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study Peter Anthony Foley, Lynda J. Spelman, Dedee Frances Murrell et al. · Australasian Journal of Dermatology Open access 11 Jul 2022 7
32 Hidradenitis Suppurativa Recurrence in a Caesarean Scar Katherine Darch, Teagan Holland, Lynda J. Spelman · Case Reports in Obstetrics and Gynecology Open access 2020 6
33 Tradeoffs and decision-making in moderate to severe psoriasis for oral versus injectable treatments: data from patients and dermatologists in Australia Saxon D. Smith, Simon J. Fifer, M S Edwards et al. · Journal of Dermatological Treatment Open access 30 Jul 2024 5
34 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials Richard Bruce Warren, April Wang Armstrong, Melinda Gooderham et al. · SKIN The Journal of Cutaneous Medicine Open access 4 Mar 2022 4
35 Development of Dermatitis Herpetiformis in Chronic Plaque Psoriasis Ruby Chia‐Lin Lee, Yolanka Lobo, Lynda J. Spelman · Case Reports in Dermatology Open access 24 Feb 2021 4
36 Conservative treatment of lentigo maligna with topical imiquimod 5% cream: a case report Yolanka Lobo, Rupert Templeman · Dermatology Online Journal Open access 2020 4
37 A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis Lynda J. Spelman, Diana M. Rubel, Alan J. M. Brnabic et al. · Journal of Dermatological Treatment Open access 21 Apr 2020 4
38 Long-Term Efficacy and Safety of Lebrikizumab Is Maintained in Patients With Moderate-to-Severe Atopic Dermatitis: Results Up to 3 Years From ADjoin Emma Guttman‐Yassky, Alan David Irvine, Eric Lawrence Simpson et al. · SKIN The Journal of Cutaneous Medicine Open access 13 Jan 2025 3
39 494 - Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis Emma Guttman‐Yassky, Stephan Weidinger, Eric Lawrence Simpson et al. · British Journal of Dermatology Feb 2024 3
40 Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program Mark Lebwohl, Richard Bruce Warren, Howard L. Sofen et al. · SKIN The Journal of Cutaneous Medicine Open access 13 Mar 2023 3
41 33259 Improvements in anxiety and depression among patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from 2 phase 3 trials (CIMPASI-1 and CIMPASI-2) April Wang Armstrong, Sandra J. McBride, Lynda J. Spelman et al. · Journal of the American Academy of Dermatology Sep 2022 3
42 27275 Atopic dermatitis treated safely with dupilumab during pregnancy: A case report and review of the literature Yolanka Lobo, Ruby Chia‐Lin Lee, Lynda J. Spelman · Journal of the American Academy of Dermatology 7 Aug 2021 3
43 An indirect comparison of long‐term efficacy of every‐2‐week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12 Kim Alexander Papp, Catherine Maari, Ashley Cauthen et al. · British Journal of Dermatology 23 Sep 2019 3
44 Deucravacitinib in Plaque Psoriasis: Laboratory Parameters Through 4 Years of Treatment in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials Neil J. Korman, Thierry Passeron, Yukari Okubo et al. · SKIN The Journal of Cutaneous Medicine Open access 18 Nov 2024 2
45 Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials April Wang Armstrong, Mark Lebwohl, Richard Bruce Warren et al. · SKIN The Journal of Cutaneous Medicine Open access 23 Jul 2024 2
46 Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis Emma Guttman‐Yassky, Stephan Weidinger, Eric Lawrence Simpson et al. · SKIN The Journal of Cutaneous Medicine Open access 13 Nov 2023 2
47 Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials Howard L. Sofen, Bruce E Strober, Shinichi Imafuku et al. · SKIN The Journal of Cutaneous Medicine Open access 13 Nov 2023 2
48 34658 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trials April Wang Armstrong, Richard Bruce Warren, Howard L. Sofen et al. · Journal of the American Academy of Dermatology Sep 2022 2
49 28171 Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2) Andrew Blauvelt, Andreas Wollenberg, Andrew Pink et al. · Journal of the American Academy of Dermatology 7 Aug 2021 2
50 15904 Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 1 Jeffrey Crowley, Neil J. Korman, Lynda J. Spelman et al. · Journal of the American Academy of Dermatology 27 Nov 2020 2

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.